Microvessel Density as a Surrogate Prognostic Marker in Patients with Multiple Myeloma: A Meta-Analysis

Background/Aims: Bone marrow (BM) angiogenesis is considered a hallmark of multiple myeloma (MM) development and progression, and can be quantified with the use of microvessel density (MVD). The purpose of this study is to provide a review and a meta-analysis of the current literature regarding the prognostic value of MVD in the overall survival (OS) of MM patients. Methods: MEDLINE was screened for studies evaluating the OS of MM patients with regard to their MVD count in BM trephine. The pooled hazard ratio (HR) and its associated 95% confidence interval (CI) among MM patients with a high and low MVD count was the primary end point. Secondary outcomes included odds ratios (OR) for 12-, 36-, and 60-month survival. Results: Ten eligible trials were identified for the analysis of the primary end point and 9 for the secondary end points. Pooled HR for OS was 1.85 (95% CI: 1.25-2.73, p = 0.002). The pooled OR of survival were 1.59 (95% CI: 1.02-2.46, p = 0.04) at 12 months, 2.90 (95% CI: 1.68-5.03, p = 0.0001) at 36 months, and 3.42 (95% CI: 2.41-4.85, p < 0.00001) at 60 months, in favor of the low MVD group. Conclusion: This meta-analysis provides persuasive evidence that MVD has significant impact on the clinical outcome of MM patients.

[1]  K. Tepetes,et al.  Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis , 2017, Journal of skin cancer.

[2]  Yibo Gao,et al.  The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous‐cell carcinoma: a meta‐analysis , 2016, Cancer medicine.

[3]  Yun Wang,et al.  Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[4]  Preeti Singh,et al.  Heparanase: From basic research to therapeutic applications in cancer and inflammation. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  P. Sonneveld,et al.  Treatment of relapsed and refractory multiple myeloma , 2016, Haematologica.

[6]  N. Jonjić,et al.  The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma. , 2016, Pathology, research and practice.

[7]  Yang Ding,et al.  High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival. , 2016, Pathology, research and practice.

[8]  Xidi Wang,et al.  The progress of angiogenic factors in the development of leukemias. , 2016, Intractable & rare diseases research.

[9]  M. Tzardi,et al.  Potential role of FLT3-ligand in the angiogenic process of multiple myeloma. , 2015, Leukemia research.

[10]  H. Eom,et al.  Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma , 2015, Annals of laboratory medicine.

[11]  Kelvin K. W. Chan,et al.  Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. , 2015, European journal of cancer.

[12]  M. Alexandrakis,et al.  Mast Cells Influence the Proliferation Rate of Myeloma Plasma Cells , 2015, Cancer investigation.

[13]  K. Sfiridaki,et al.  Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma , 2015, Journal of Cancer Research and Clinical Oncology.

[14]  M. Alexandrakis,et al.  Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity , 2015, Medical Oncology.

[15]  A. Alegakis,et al.  Prognostic impact of angiopoietin-2 in multiple myeloma , 2014, Journal of Cancer Research and Clinical Oncology.

[16]  K. Lisy.  Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. , 2013, Clinical journal of oncology nursing.

[17]  P. Kanellou,et al.  Role of platelet‐derived growth factor‐AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma , 2012, Hematological oncology.

[18]  K. Anderson.  The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Ribatti,et al.  Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells , 2010, Leukemia.

[20]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[21]  H. Goldschmidt,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Seema Sharma,et al.  Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors , 2010, Annals of Hematology.

[23]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[24]  O. Markovic,et al.  Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance , 2008, Medical oncology.

[25]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[26]  Christian Jakob,et al.  Angiogenesis in multiple myeloma. , 2006, European journal of cancer.

[27]  M. Gazouli,et al.  Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer , 2006, International Journal of Colorectal Disease.

[28]  D. Ribatti,et al.  Bone marrow angiogenesis in multiple myeloma , 2006, Leukemia.

[29]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. B. Sørensen,et al.  Syndecan‐1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival , 2005, British journal of haematology.

[31]  E. Stathopoulos,et al.  Bone marrow microvascular density and angiogenic growth factors in multiple myeloma , 2004, Clinical chemistry and laboratory medicine.

[32]  Santhosh K. P. Kumar,et al.  Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy , 2004, Bone Marrow Transplantation.

[33]  N. Agnantis,et al.  Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. , 2004, In vivo.

[34]  S. Szabó,et al.  The diagnostic and prognostic value of tumor angiogenesis. , 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[35]  O. Sezer,et al.  Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III , 2003, Journal of Cancer Research and Clinical Oncology.

[36]  H. Goldschmidt,et al.  Angiogenesis in hematologic malignancies. , 2003, Annals of hematology.

[37]  R. Fonseca,et al.  Bone marrow angiogenesis in multiple myeloma: effect of therapy , 2002, British journal of haematology.

[38]  G. Pruneri,et al.  Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients , 2002, British journal of haematology.

[39]  R. Fonseca,et al.  Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[41]  S. Rajkumar,et al.  A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. , 2002, Journal of hematotherapy & stem cell research.

[42]  S. Molica,et al.  Angiogenesis in Chronic Myeloproliferative Diseases , 2002, Acta Haematologica.

[43]  N. Munshi,et al.  Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. , 2001, Seminars in oncology.

[44]  H. Goldschmidt,et al.  Angiogenesis in hematologic malignancies , 2001, Annals of Hematology.

[45]  A. Harris,et al.  Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.

[46]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[47]  S. Rajkumar,et al.  Angiogenesis in multiple myeloma , 2001, British journal of haematology.

[48]  O. Bairey,et al.  Bcl‐2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia , 2001, British journal of haematology.

[49]  O. Sezer,et al.  Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy , 2001, European journal of haematology.

[50]  K. Wernecke,et al.  Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.

[51]  Junghye Choi,et al.  Clinical significance of microvessel density in multiple myeloma patients. , 2001, Journal of Korean medical science.

[52]  J. Cawley,et al.  In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. , 2000, Blood.

[53]  M. Dietel,et al.  Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma , 2000, Annals of Hematology.

[54]  M. Mangi,et al.  ANGIOGENESIS and ANGIOGENIC MEDIATORS IN HAEMATOLOGICAL MALIGNANCIES , 2000, British journal of haematology.

[55]  R. Fonseca,et al.  Prognostic value of bone marrow angiogenesis in multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  B. Barlogie,et al.  Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. , 2000, Blood.

[57]  W. Berdel,et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. , 2000, Blood.

[58]  S. Molica,et al.  Increased serum levels of vascular endothelial growth factor predict risk of progression in early B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.

[59]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[60]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[61]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[62]  R. Nicosia.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? , 1998, The American journal of pathology.

[63]  G. Martiny-Baron,et al.  The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities , 1998, Cancer and Metastasis Reviews.

[64]  Wilkinson,et al.  Tumour angiogenesis and prognosis , 1998, Histopathology.

[65]  H. Stein,et al.  Expression of vascular endothelial growth factor in lymphomas and castleman's disease , 1997, The Journal of pathology.

[66]  S. Sallan,et al.  Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. , 1997, The American journal of pathology.

[67]  Stephen B. Fox,et al.  COMMENTARY Tumour angiogenesis and prognosis , 1997, Histopathology.

[68]  E. Abel.  Clinical applications of research on angiogenesis , 1996 .

[69]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[70]  D. Ribatti,et al.  Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. , 1995, Leukemia & lymphoma.

[71]  D. Ribatti,et al.  Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.

[72]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[73]  J. Gabrilove,et al.  Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. , 1993, Blood.

[74]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[75]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[76]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[77]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[78]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[79]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[80]  B. Himani,et al.  Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[81]  S. Lonial,et al.  New Targets and New Agents in High-Risk Multiple Myeloma. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[82]  M. Dimopoulos,et al.  Current treatment landscape for relapsed and/or refractory multiple myeloma , 2015, Nature Reviews Clinical Oncology.

[83]  J. Shah,et al.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) , 2014, Leukemia.

[84]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[85]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[86]  H. Goldschmidt,et al.  Therapy of relapsed and refractory multiple myeloma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[87]  S. Rosati,et al.  Bcl-xl expression in multiple myeloma , 2005, Medical oncology.

[88]  N. Kay,et al.  Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia , 2000, Leukemia.

[89]  F. Di Raimondo,et al.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. , 2000, Haematologica.

[90]  E. Estey,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use , 2000 .

[91]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[92]  J. Folkman.  Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[93]  K. Lee,et al.  Cancer Research Campaign , 1991 .

[94]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[95]  Wei-Mou Zheng,et al.  T E C H N I C a L a D V a N C E Open Access , 2022 .